HS
IMVT icon

HighVista Strategies’s Immunovant IMVT Stock Holding History

HighVista Strategies’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Buy
277,873
+52,734
+23% +$1.61M 2.44% 5
2026
Q1 		$5.59M Buy
225,139
+3,256
+1% +$84.3K 1.54% 11
2025
Q4 		$5.64M Sell
221,883
-31,244
-12% -$697K 1.45% 19
2025
Q3 		$4.08M Buy
253,127
+70,319
+38% +$1.14M 1% 25
2025
Q2 		$2.92M Buy
182,808
+87,160
+91% +$1.32M 1.07% 18
2025
Q1 		$1.63M Buy
+95,648
New +$2M 0.63% 57
2024
Q1 		– Sell
-121,287
Closed -$5.11M – 141
2023
Q4 		$5.11M Buy
121,287
+14,379
+13% +$529K 1.85% 4
2023
Q3 		$4.1M Sell
106,908
-73,412
-41% -$1.66M 1.9% 5
2023
Q2 		$3.42M Buy
180,320
+16,521
+10% +$308K 1.57% 14
2023
Q1 		$2.54M Buy
+163,799
New +$2.84M 2.07% 14
2021
Q1 		– Sell
-17,905
Closed -$827K – 134
2020
Q4 		$827K Hold
17,905
– – 0.53% 41
2020
Q3 		$630K Buy
+17,905
New +$539K 0.46% 26

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HighVista Strategies's IMVT Position: Q2 2026 in Review

HighVista Strategies increased its Immunovant (IMVT) stake by 23% in Q2 2026, buying an estimated $1.61M and bringing the position to 277,873 shares worth $10.7M. The position accounts for 2.44% of the portfolio, ranked #5.

HighVista Strategies first reported a position in IMVT in Q3 2020 and has held it in 12 quarters since. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • HighVista Strategies held 277,873 shares of Immunovant worth $10.7M as of Q2 2026.
  • HighVista Strategies bought 52,734 Immunovant shares in Q2 2026, an estimated $1.61M.
  • Immunovant made up 2.44% of HighVista Strategies's portfolio in Q2 2026, its #5 holding.
  • HighVista Strategies first reported a position in Immunovant in Q3 2020 and has held it in 12 quarters since.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.